TABLE 1.

Meningococcal Disease Sequelae Probabilities, HUIs, Vaccine Efficacy, and Coverage Assumptions

Base CaseRangeDistributionRef No(s).
Sequelae, proportion (%) of survivors with
    Skin scarring, %7.60–19%Nml, trunc16, 56
    Single amputation, %1.90.5–10%Nml, trunc16, 56, 57
    Multiple amputations, %1.20.02–6%Nml, trunc16, 57
    Hearing loss, %6.42–20%Nml, trunc15, 16, 58
    Neurologic disability, %2.10.02–11%Nml, trunc15, 56, 57
HUIs
    Skin scarring1.00.8–1.0None2123
    Single amputation0.7100.31–0.8Triang59, 60
    Multiple amputations0.6130.31–0.71Triang24, 59, 60
    Hearing loss0.7230.64–0.82Uniform25, 39
    Neurologic disability0.0600–0.39Uniform26
Initial vaccine efficacy
    Infant vaccinated, %91.565–98%Triang, trunc6
    Toddler vaccinated, %9265–98%Triang, trunc10
    Adolescent vaccinated, %9378–98%Triang, trunc27
Vaccination coverage
    Infants (5–11 months of age), %7734–90%Lognorm, trunc32
    Infants (≥1 year of age)9381–96%Triang32, 61
    Toddlers, %9154–98%Triang32
    Adolescents, %7116–95%Lognorm, trunc33
  • Triang indicates triangular; trunc, truncated; lognorm, log normal; nml, normal.